By DoM Communications | Date published: November 17, 2025

 Mark Klempner Leads Research Team in Developing Safe and Effective Rabies Treatment 

Rabies is one of the deadliest infectious diseases, but it can be prevented when treated quickly after an animal bite. Mark Klempner, MD, professor of medicine, is the leader of the research team that helped develop Rabishield, a monoclonal antibody therapy developed by UMass Chan Medical School in partnership with the Serum Institute of India, which offers a safe and effective alternative to older rabies treatments. In 2017, the Serum Institute of India announced the global launch of Rabishield, a US-patented product, in an effort to close the gaps in rabies prevention and reduce the rabies mortality rate in India. 

Learn more by reading the full story in UMass Chan News.